---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-004066"
form_type: "8-K"
ticker: "PALI"
cik: "0001357459"
company_name: "PALISADE BIO, INC."
filed_at: "2024-01-29T23:59:59+00:00"
generated_at: "2026-06-06T15:47:39.720118+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Palisade Bio reports positive preclinical data for PALI-2108 UC therapy; Phase 1 planned for 2024

## Summary
- PALI-2108 showed colon-selective bioactivation with colon/plasma AUC ratio >200.
- In DSS-induced UC mouse model, significant reduction in disease activity index over time.
- No CNS toxicity or emesis observed in dogs at effective doses.
- Company advancing PALI-2108 toward Phase 1 clinical study, expected to start in 2024.

## SEC filing metadata
- accession: 0001493152-24-004066
- form_type: 8-K
- ticker: PALI
- cik: 0001357459
- company_name: PALISADE BIO, INC.
- filed_at: 2024-01-29T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1357459/000149315224004066/0001493152-24-004066-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1357459/000149315224004066/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-004066
- JSON: https://secwatch.observer/filing/0001493152-24-004066.json
- Plain text: https://secwatch.observer/filing/0001493152-24-004066.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.